Geode Capital Management LLC Grows Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)

Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) by 22.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 192,563 shares of the company’s stock after purchasing an additional 35,821 shares during the quarter. Geode Capital Management LLC owned about 0.76% of MAIA Biotechnology worth $541,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, XTX Topco Ltd acquired a new stake in shares of MAIA Biotechnology during the third quarter worth about $31,000. 5.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Stan Smith purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the purchase, the director now directly owns 1,130,060 shares of the company’s stock, valued at $2,113,212.20. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Cristian Luput purchased 22,133 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, with a total value of $55,553.83. Following the purchase, the director now directly owns 389,483 shares of the company’s stock, valued at $977,602.33. The trade was a 6.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 36.98% of the company’s stock.

MAIA Biotechnology Stock Down 0.5 %

NYSEAMERICAN MAIA opened at $2.12 on Friday. MAIA Biotechnology, Inc. has a one year low of $0.99 and a one year high of $5.99. The company has a market capitalization of $53.70 million, a PE ratio of -1.54 and a beta of 0.14.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.21. Equities research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current year.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.